Glucagon-like peptide 1 receptor agonists (GLP-1RAs) demonstrate glucose-lowering, weight-reducing, and favourable anti-inflammatory and metabolic effects.1 These emerging drug classes have been proven to reduce cardiovascular events in patients with type 2 diabetes mellitus (T2DM) who are at high cardiovascular risk or have established cardiovascular disease.2 In this context, current guidelines recommend GLP-1RAs as first-line antidiabetic therapies in patients with established cardiovascular disease or high/very high cardiovascular risk.3 Semaglutide is a potent GLP-1RA used in the treatment of T2DM, with demonstrated cardiovascular benefits
Consistent with other GLP-1 receptor agonists
Proton transfer in fluorescent secondary amines: synthesis, photophysics, theoretical calculation and preparation of photoactive phosphatidylcholine-based liposomes
Confirm the trend, check for missed doses and side effects, and speak with your clinician if the weekly average has not changed for about a month
Turn the dose selector until your prescribed dose appears (0.25 mg, 0.5 mg, 1 mg, or 2 mg)
Minimizing reactions: Tips for patients Patients can take several proactive steps to reduce the likelihood and severity of injection site reactions when using tirzepatide injection